Search Results

You are looking at 201 - 210 of 2,852 items for :

  • Refine by Access: All x
Clear All
Full access

HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia

Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai

decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a

Full access

QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines

Kristen Burns, Archana Shenoy, and Nicole Turkoglu

population, examine policy and nursing practices to better navigate patients through the continuum of oncology care and improve patient outcomes. The purpose is to describe how the formation of an evidence-based practice committee can engage specialized

Full access

CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma

Karen Valdés-Díaz, Halbert Hernández-Negrín, Leonel Valdés-Leiva, Diana Martin-Oliva, and Dianelys Pedraza-González

Background: Comorbidity in elderly has made it difficult to manage when they are affected by aggressive non-Hodgkin's lymphoma. This has led to the historical achievement of poor outcomes, hence the analysis of the impact of comorbidity in this

Full access

CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients

Yunyun Liu, KKL Chan, and Hui Zhou

relapse, indicating that the poorer outcome of patients with NACT>3 may not be caused by chemo-induced resistance. The reason of worse outcomes after more cycles of NACT is still needed to be explored. CLO22-060 Figure 1 CLO22-060 Table 1

Full access

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

equivalent for >4 weeks receive antimicrobial prophylaxis for Pneumocystis jirovecii pneumonia (PJP). Limited data exist regarding the incidence and outcome of OIs among patients receiving ICIs who need SS and/or ISAs for >4 weeks to manage irAEs

Full access

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

scan. Outcomes would be expected to differ significantly between these groups. Andre et al. 5 retrospectively analyzed data on 702 consecutive patients with N2 disease at 6 French centers and found that the degree of N2 involvement correlated with

Full access

Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing

Noman Ashraf, Nishi Kothari, and Richard Kim

agents and targeted therapies against both vascular endothelial growth factor and epidermal growth factor receptor (EGFR), survival has improved. However, outcomes remain highly variable because CRC is a heterogeneous multipathway disease. 2 , 3 It is

Full access

Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and

Full access

HSR24-160: Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies

John Sharp, Cassandra Pasadyn, Songzhu Zhao, Lai Wei, Carolyn Presley, Dwight Owen, Kathleen Wyne, and Alexa Meara

1 diabetes mellitus (T1D), occurring in less than 1% of patients. ICI-induced T1D is notable for its acute onset, potentially life-threatening presentation of diabetic ketoacidosis (DKA), and irreversibility. Data on long term outcomes for these

Full access

CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer

Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem

in ongoing phase III clinical trials. This study aims to understand the prevalence, current treatment patterns and outcomes of HER2-low patients. Methods : This descriptive study analyzed data from a patient tumor registry in the Huntsman Cancer